Spectroscopic and Biochemical Characterisation of Self-Aggregates Formed by Antitumor Drugs of the Camptothecin Family

Pommier, 1993, Mammalian DNA topoisomerase I and its inhibitors, 214 Hsiang, 1985, Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I, J Biol Chem, 260, 14873, 10.1016/S0021-9258(17)38654-4 Jaxel, 1989, Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I, Cancer Res, 49, 5077 Burke, 1993, Lipid bilayer partitioning and stability of camptothecin drugs, Biochemistry, 32, 5352, 10.1021/bi00071a010 Burke, 1994, The structural basis of camptothecin interactions with human serum albumin, J Med Chem, 37, 40, 10.1021/jm00027a005 Nabiev, 1994, Molecular interactions of DNA-topoisomerase I and II inhibitor with DNA and topoisomerases and in ternary complexes, Biochemistry, 33, 9013, 10.1021/bi00196a020 Morjani, 1993, Molecular and cellular interactions between Intoplicine, DNA, and topoisomerase II studied by surface-enhanced Raman scattering spectroscopy, Cancer Res, 53, 4784 Jaxel, 1991, Effect of local DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin, J Biol Chem, 266, 20418, 10.1016/S0021-9258(18)54939-5 Lozzio, 1975, Human chronic myelogenous leukemia cell line with positive Philadelphia chromosome, Blood, 45, 321, 10.1182/blood.V45.3.321.321 Gottesman, 1993, Biochemistry of multidrug resistance mediated by the multidrug transporter, Annu Rev Biochem, 62, 385, 10.1146/annurev.bi.62.070193.002125 Akimoto, 1994, Kinetic studies of the hydrolysis and lactonization of camptothecin and its derivatives, CPT11 and SN-38, in aqueous solution, Chem Pharm Bull, 42, 2135, 10.1248/cpb.42.2135 Fassberg, 1992, A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues, J Pharm Sci, 81, 676, 10.1002/jps.2600810718 UV-vis Atlas of Organic Compounds (1966–1971) Vol. 1–5. Verlag Chemie, Weinheim, Butterworths, London. Wheeler OH and Kaplan L, Organic Electronic Spectra Data, Vol. 3. Interscience, New York, 1966. Davydov, 1962 Kasha, 1965, The exciton model in molecular spectroscopy, Pure Appl Chem, 11, 371, 10.1351/pac196511030371 Knapp, 1984, Exchange narrowing of correlated inhomogeneities. The dimer linshape, Chem Phys Lett, 103, 479, 10.1016/0009-2614(84)85281-1 Knapp, 1984, Lineshapes of molecular aggregates. Exchange narrowing and intersite correlation, Chem Phys, 85, 73, 10.1016/S0301-0104(84)85174-5 Band, 1975, Engineering reverse saturable absorbers for desired wavelengths, Chem Phys Lett, 127, 381, 10.1016/0009-2614(86)80300-1 Yoshioka, 1971, Crystal structures of two photographic sensitizing dyes. 1,1′-Diethyl-2,2′-cyanine bromide and 1,1′-diethyl-4,4′-cyanine bromide, Chem Phys Lett, 11, 255, 10.1016/0009-2614(71)80477-3 Wani, 1987, Plant antitumor agents. 28. Resolution of a key tricyclic synthon, 5′(RS)-1,5-dioxo-5′-ethyl-5′-hydroxy-2′H,6′H-oxopyrano[3′,4′-f]delta 6,8-tetrahydro-indolizine, J Med Chem, 30, 2317, 10.1021/jm00395a024 Hertzberg, 1989, On the mechanism of topoisomerase I inhibition by camptothecin, Biochemistry, 28, 4629, 10.1021/bi00437a018 Wall, 1991 Costin D, Silber R, Canellakis ZN, Morse L and Potmesil M, DNA Topoisomerases in Therapy. New York University Medical Center, New York, 1992. Chen, 1991, Camptothecin overcomes MDR 1-mediated resistance in human KB carcinoma cells, Cancer Res, 51, 6039 Litovchik, 1995, Camptothecin-topoisomerase I interaction as probed by fluorescence spectroscopy, Dokl Akad Nauk, 340, 271